drugset / Trial / NCT00836693

Effect of Tadalafil Once a Day in Men With Erectile Dysfunction

NCT00836693

Phase 3 Completed 217 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ED) who are naïve to PDE5 (phosphodiesterase type 5) inhibitors. Patients may be dose reduced to 2.5mg based on tolerability.

Timeline

Start
2009-01
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 5 mg Oral

Indications